AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
AYTU BIOPHARMA, INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026
$1.96−0.08 (-3.92%)
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$10.96M
$1.86M due within a year
Net debt
-$15.35M
After $26.31M of cash
Implied interest rate
15.98%
FY2026 interest ÷ average debt
Interest coverage
-4.4×
FY2026 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Aytu Biopharma's annual report. Trading prices and yields need FINRA TRACE data.